LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC)

Clinical trials for LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC) explained in plain language.

Never miss a new study

Get alerted when new LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC) trials appear

Sign up with your email to follow new studies for LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 1

New drug duo tested to keep aggressive lung cancer at bay

Disease control Not yet recruiting

This study is testing whether adding two drugs, tislelizumab and nintedanib, can help people with limited-stage small cell lung cancer live longer without their cancer getting worse. The drugs are given after patients finish their standard chemotherapy and radiation treatment. Th…

Matched conditions: LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC)

Phase: PHASE4 • Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control

Last updated Mar 27, 2026 12:38 UTC

LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC)

Get alerted when new LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC) trials appear

New drug duo tested to keep aggressive lung cancer at bay